Basic Information
| LncRNA/CircRNA Name | LINCRNA-p21 |
| Synonyms | TP53COR1, TRP53COR1, linc-p21, lincRNA-p21 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | hepatocellular carcinoma tissues, cell lines (L02, HepG2, SMMC7721, Hep3B, MHCC97H and SK-Hep1) |
| Expression Pattern | down-regulated |
| Function Description | The effects of miR-9 on HCC cells were studied by using miR-9 inhibitor in vitro. Luciferase assay was used to validate the target of miR-9. The results showed that lincRNA-p21 was downregulated in human HCC tissues and cell lines. LincRNA-p21 overexpression significantly inhibited HCC cell migration and invasion in vitro. Besides, lincRNA-p21 negatively regulated miR-9 expression level, and miR-9 was upregulated in human HCC tissues and cells. MiR-9 knockdown inhibited HCC cell migration and invasion in vitro. Finally,E-cadherin was a direct target of miR-9. The expression level of E-cadherin was found to be regulated by lincRNA-p21 and miR-9. |
| Pubmed ID | 28721075 |
| Year | 2017 |
| Title | LincRNA-p21 inhibits invasion and metastasis of hepatocellular carcinoma through miR-9/E-cadherin cascade signaling pathway molecular mechanism. |
External Links
| Links for LINCRNA-p21 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |